AVITA MEDICAL INC (AVH)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AVH - AVITA MEDICAL INC

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.34
Index: ALL-ORDS

Avita Medical is developing and marketing a range of regenerative skin products. It is headquartered in California and listed on the ASX and NASDAQ.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$3.03

01 Nov
2024

-0.160

OPEN

$3.08

-5.02%

HIGH

$3.10

79,498

LOW

$3.03

TARGET
$4.52 49.2% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . BIO . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
AVH: 1
Title FY24
Forecast		 FY25
Forecast
EPS (cps) - 185.3 xxx
DPS (cps) 0.0 xxx
EPS Growth N/A xxx
DPS Growth N/A xxx
PE Ratio N/A xxx
Dividend Yield 0.0% xxx
Div Pay Ratio(%) N/A xxx
This company reports in USD.
All estimates have been converted into AUD by FNArena at present FX values.

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-42.1
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx75.5 M
Book Value Per Share xxxxxxxxxxxxxxx56.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-57.3 M
Net Profit Margin xxxxxxxxxxxxxxx-70.56 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-54.16 %
Return on Invested Capital xxxxxxxxxxxxxxx-41.30 %
Return on Assets xxxxxxxxxxxxxxx-34.56 %
Return on Equity xxxxxxxxxxxxxxx-54.16 %
Return on Total Capital xxxxxxxxxxxxxxx-142.42 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-59.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx61 M
Total Debt xxxxxxxxxxxxxxx62 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx131 M
Price To Book Value xxxxxxxxxxxxxxx7.66

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx2.2 M
Capex % of Sales xxxxxxxxxxxxxxx2.89 %
Cost of Goods Sold xxxxxxxxxxxxxxx12 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx249 M
Research & Development xxxxxxxxxxxxxxx31 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.8

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxxxxxx xx xxxxxxxxxxx xxx xxxx xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

12/08/2024

1

Add

$4.56

50.50%

Despite in-line 1H results, Morgans lowers its target for Avita Medical to $4.56 from $5.60 due to a -14% downgrade to FY24 revenue guidance. The fall in target is also partly due to a new analyst taking up coverage.

Nonetheless, management maintained FY24 profitability guidance for cash flow breakeven and profitability no later than Q3 FY25 due to revenue growth, high gross margins and a stable cost base, explains the broker.

The Add rating is maintained.

FORECAST
Morgans forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -53.25 cents.
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -16.60 cents.

Ord Minnett

xx/xx/xxxx

2

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

15/08/2024

3

Market Weight

$2.75

-9.24%

Avita Medical offered 3Q24 guidance revenue including a strong July, but revised down the FY24 guidance range which equated to a -14% downgrade, Wilsons notes.

The broker notes the market ignored the guidance update and pushed the stock higher in the US on the back of good early progress in Recell Go, which reduces the potential revenue gap from the launch of the full-thickness skin defects product. 

The analyst highlights the pull forward of revenue income from Recell assists with debt covenants and capital management.

Market Weight retained. Target price revised to $2.75.

FORECAST
Wilsons forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -62.15 cents.
Wilsons forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -27.61 cents.
Access Extra Coverage Research History >

AVH STOCK CHART

FNArena News on AVH

1
Rudi’s View: Banks, Miners & Quality Small Caps

Sep 26 2024 - Rudi's View
2
Rudi’s View: Key Picks, Best Buys & Conviction Calls

Sep 12 2024 - Rudi's View
3
Weekly Ratings, Targets, Forecast Changes – 16-08-24

Aug 19 2024 - Weekly Reports
4
Australian Broker Call *Extra* Edition – Aug 15, 2024

Aug 15 2024 - Daily Market Reports
5
Rudi’s View: Model Portfolios, Best Ideas & Conviction Calls

Aug 15 2024 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps